Cardiology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Asymptomatic atrial fibrillation is associated with elderly age, more comorbidities, and high thromboembolic risks

Atrial fibrillation is often asymptomatic, but outcomes require further characterization. The study objective was to investigate the clinical presentation, management, and outcomes in asymptomatic and symptomatic patients with atrial fibrillation who were prospectively enrolled in the EurObservational Research Programme - Atrial Fibrillation ( EORP-AF ) Pilot General Registry.

A total of 3119 patients were enrolled, and 1237 ( 39.7% ) were asymptomatic ( European Heart Rhythm Association [ EHRA ] score I ).
Among symptomatic patients, 963 ( 51.2% ) had mild symptoms ( EHRA score II ) and 919 ( 48.8% ) had severe or disabling symptoms ( EHRA III-IV ).

Permanent atrial fibrillation was 3-fold more common in asymptomatic patients than in symptomatic patients.

On multivariate analysis, male gender ( odds ratio [ OR ], 1.630; 95% confidence interval [ CI ], 1.384-1.921 ), older age ( OR, 1.019; 95% CI, 1.012-1.026 ), previous myocardial infarction ( OR, 1.681; 95% CI, 1.350-2.093 ), and limited physical activity ( OR, 1.757; 95% CI, 1.495-2.064 ) were associated significantly with asymptomatic ( EHRA I ) atrial fibrillation.

Fully asymptomatic atrial fibrillation ( absence of current and previous symptoms ) was present in 520 patients ( 16.7% ) and was associated independently with male gender, age, and previous myocardial infarction.

Appropriate guideline-based prescription of oral anticoagulants was lower in these patients, and Acetylsalicylic acid ( Aspirin ) was prescribed more frequently.

Mortality at 1 year was more than 2-fold higher in asymptomatic patients compared with symptomatic patients ( 9.4% vs 4.2%, P less than 0.0001 ) and was associated independently with older age and comorbidities, including chronic kidney disease and chronic heart failure.

In conclusion, asymptomatic atrial fibrillation is common in daily cardiology practice and is associated with elderly age, more comorbidities, and high thromboembolic risks.
A higher 1-year mortality was found in asymptomatic patients compared with symptomatic patients. ( Xagena )

Boriani G et al, Am J Med 2015;128:509-518